Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission

Zosano Pharma's migraines are getting worse: The biotech is looking at strategic alternatives and laying off 31% of its staff. The news follows last month's FDA decision to decline to review the company's already-rejected drug.